http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6136229-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d64b436b4156e913242049f007a8134b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ece786f89987d435ce5dd750249eff8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0791f3780ea610e4c89c0ad01eb9834
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
filingDate 1984-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea89b89803cabe2e63ffcae5f4a97c55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_453d90df5affc3784a70d8f463d57217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a534fea706454e33e1541a2225c035fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f281980533d13dd1e00c4ca6f431154c
publicationDate 1986-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S6136229-A
titleOfInvention Selectively carcinostatic substance
abstract PURPOSE: The titled carcinostatic substance having high affinity for CEA-forming cancer, showing no affinity for normal cells at all, consisting of a reaction product of an anti-human CEA monoclonal antibody and neocarzinostatin. n CONSTITUTION: A chemical reaction product of an anti-human CEA monoclonal antibody (e.g., anti-human colon cancer monoclonal antibody) and neocarzinostatin (NCS for short). NCS is a compound wherein a chromophore having about 700 molecular weight is bonded to an acidic protein having about 10,700 molecular weight consisting of 109 amino acid, shows strong carcinostatic action, but has side effect to have actions on normal cell simultaneously. Bonding of the monoclonal antibody having selective affinity for CEA-forming cancer to it provides the selective carcinostatic substance having high selectivity only for cancerous cells, longer durability in blood than NCS, and lower toxicity. Colon cancer, stomach cancer, etc. may be cited as the human CEA-forming cancer. n COPYRIGHT: (C)1986,JPO&Japio
priorityDate 1984-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5843926-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419584834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412254
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447545
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57125363

Total number of triples: 30.